查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非霍奇金淋巴瘤治療全球市場規模研究與預測：按疾病類型、分銷渠道和地區分析，2022-2029 年
市場調查報告書
商品編碼
1251575

非霍奇金淋巴瘤治療全球市場規模研究與預測：按疾病類型、分銷渠道和地區分析，2022-2029 年

Global Non - Hodgkin Lymphoma Therapeutics Market Size study & Forecast, by Type of Therapy by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球非霍奇金淋巴瘤治療市場價值約為 83.3 億美元，預計在 2022-2029 年預測期內將以約 8.50% 的健康增長率增長。

非霍奇金淋巴瘤（NHL）是一種在人體內產生異常淋巴細胞的疾病。除非接受治療，否則這些淋巴細胞不會死亡並會在體內繼續生長和分裂。NHL 通常始於淋巴結，但如果不及時治療，可以擴散到整個淋巴系統。非霍奇金淋巴瘤治療市場根據類型、治療類型、給藥途徑、分銷渠道和最終用戶進行細分。行業的市場增長從這些細分市場的增長中進行檢查，並幫助用戶為您提供市場洞察力的概述，並做出對核心市場應用程序進行分類的決策。

非霍奇金淋巴瘤事件的增加導致市場增長，目前幾乎所有類型癌症（包括某些類型的非霍奇金淋巴瘤）的高患病率趨勢都是難治性或惡化的。需要更好的臨床和挽救結果非霍奇金淋巴瘤患者是一個重要的驅動因素。在開發針對多種類型的非霍奇金淋巴瘤的有效治療方法方面，持續不斷地加大研發力度是主要驅動力之一。市場參與者增加投資也是長期增長的一個因素。對口服藥物的需求不斷增長也促進了大多數產品以膠囊或片劑形式提供的市場的增長。

新興市場批准療法的成本上升限制了先進療法的採用。非霍奇金淋巴瘤治療市場的增長是由某些類型的治療（如免疫療法）的高成本推動的。在預測期內，缺乏對非霍奇金淋巴瘤治療不了解的訓練有素的專業人員可能會抑制全球非霍奇金淋巴瘤市場的增長。

此外，公眾健康意識的提高也極大地推動了市場的增長。據美國癌症協會稱，估計有 80,470 人患有非霍奇金淋巴瘤。發病率最高的似乎是女性 80-84 歲和男性 85-89 歲之間的年齡組。對更好的臨床實踐以有效治療患者的不斷增長的需求正在推動市場增長。

全球非霍奇金淋巴瘤治療市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。北美由於其對所有形式癌症（包括非霍奇金淋巴瘤等各種血液癌症）的高患病率和認識而佔據市場主導地位。因此，非霍奇金淋巴瘤正在接受昂貴的療法，例如免疫療法。在預測期內，亞太地區將成為增長最快的市場。日本位於亞太地區，人口眾多，批准了 Kimia 等昂貴的治療藥物，這有助於亞太市場的增長。

目錄

第一章執行摘要

  • 市場快照
  • 2019-2029 年按細分市場的全球市場估計和預測
    • 2019-2029 年按地區分列的非霍奇金淋巴瘤治療市場
    • 非霍奇金淋巴瘤治療市場，按療法，2019-2029
    • 非霍奇金淋巴瘤治療市場，按疾病分類，2019-2029
    • 非霍奇金淋巴瘤治療市場，按分佈，2019-2029
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第二章全球非霍奇金淋巴瘤治療市場定義和範圍

  • 研究目標
  • 市場定義和範圍
    • 調查範圍
    • 產業進化
  • 本次調查涵蓋的年份
  • 貨幣兌換率

第三章非霍奇金淋巴瘤藥物的全球市場動態

  • 非霍奇金淋巴瘤藥物市場影響分析（2019-2029）
    • 市場驅動力
      • 市場參與者增加投資
      • 對口服藥物的需求不斷增長
    • 市場挑戰
      • 關於非霍奇金淋巴瘤的高昂治療費用
    • 市場機會
      • 非霍奇金淋巴瘤增加
      • 保健意識不斷增強

第四章非霍奇金淋巴瘤治療的全球市場行業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭對手之間的競爭
  • 波特五力模型的未來方法（2019-2029）
  • PEST分析
    • 政治的
    • 經濟的
    • 社會的
    • 技術的
  • 招商引資模式
  • 分析師的建議和結論
  • 最佳投資機會
  • 關鍵成功策略

第 5 章風險評估 COVID-19 影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

6 非霍奇金淋巴瘤治療的全球市場，按療法

  • 市場快照
  • 全球非霍奇金淋巴瘤治療藥物市場：按療法、按性能 - 潛力分析
  • 2019-2029 年全球非霍奇金淋巴瘤藥物市場按療法估計和預測
  • 非霍奇金淋巴瘤治療市場，細分分析
    • 化學處理
    • 靶向治療
    • 免疫療法
    • 其他

7 非霍奇金淋巴瘤治療的全球市場，按疾病類型

  • 市場快照
  • 非霍奇金淋巴瘤療法的全球市場：按疾病類型進行的性能潛力分析
  • 2019-2029 年按疾病類型分列的全球非霍奇金淋巴瘤藥物市場估計和預測
  • 非霍奇金淋巴瘤治療市場，細分分析
    • B細胞淋巴瘤
    • T細胞淋巴瘤

8 全球非霍奇金淋巴瘤治療市場，按分銷渠道

  • 市場快照
  • 非霍奇金淋巴瘤治療藥物的全球市場：按分銷渠道進行的性能潛力分析
  • 2019-2029 年按分銷渠道分列的全球非霍奇金淋巴瘤藥物市場估計和預測
  • 非霍奇金淋巴瘤治療市場，細分分析
    • 醫院藥房
    • 零售藥店
    • 其他

9 非霍奇金淋巴瘤治療的全球市場：區域分析

  • 非霍奇金淋巴瘤治療市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年各療法的估計和預測
      • 2019-2029 年各疾病類型的估計和預測
      • 2019-2029 年各分銷渠道的估計和預測
    • 加拿大
  • 歐洲非霍奇金淋巴瘤藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 歐洲其他地區
  • 亞太非霍奇金淋巴瘤藥物市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲非霍奇金淋巴瘤藥物市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第 10 章 競爭信息

  • 頂級市場戰略
  • 公司簡介
    • Takeda Pharmaceutical Company Limited
      • 主要信息
      • 概述
      • 財務（僅當數據可用時）
      • 產品概要
      • 最近的發展
    • AstraZeneca plc
    • Bayer AG
    • Novartis AG
    • Kyowa Kirin Co. Ltd.
    • Bristol Myers Squibb Company
    • Janssen Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Sanofi India
    • AbbVie. Inc

第十一章調查過程

  • 調查過程
    • 數據挖掘
    • 分析
    • 市場估計
    • 驗證
    • 出版物
  • 調查特點
  • 調查先決條件

Global Non - Hodgkin Lymphoma Therapeutics Market is valued at approximately USD 8.33 billion in 2021 and is anticipated to grow with a healthy growth rate of around 8.50% over the forecast period 2022-2029. Non- Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time, then it might spread to the entire lymphatic system. The Non- Hodgkin lymphoma therapeutics market is subdivided on basis of type, treatment type, route of administration, distribution channel and end user. The market growth of industries will get inspected from the growth of these segments and help the users to overview you the market insights and helps to make decisions for classifying core market application.

Increasing events of Non-Hodgkin Lymphomas lead to Market Growth and are the current trends of higher prevalence of almost all types of cancer which also includes several types of NHL The need for better clinical and remedial results for the patients for non-Hodgkin lymphoma where the disease has become refractory or deteriorated is a critical driving factor. Ongoing and increased R&D activity in the development of efficient therapeutics for a number of types of NHL are one of the key driving factors. Along with an increasing investment by market players also a factor for long term growth. The rising demand for oral drugs has also contributed to the market growth where most products are available in capsule and tablet form.

Increased cost of approved Therapeutics in Emerging countries leads to curb the Adoption of advanced Therapeutics. The non-Hodgkin lymphoma treatment market growth is affected by the high cost imputed to certain types of therapies like immunotherapies. Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global non-Hodgkin lymphoma market over a forecast period.

As Health Awareness increasing among the population also indicates a major boost to the market growth. According to the American Cancer Society, non-Hodgkin lymphoma is estimated to be around 80, 470. The Highest rates are likely to be in the age group between 80-84 years for females and 85-89 years for males. The need for better clinical are required more and more to treat the patients effectively which drives the market growth.

The key regions considered for the Global Non - Hodgkin Lymphoma Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market due to high prevalence and awareness of all forms of cancer including various blood cancers such as non-Hodgkin's lymphoma. These led to adoption of expensive form of therapies for treatment of NHL such as immunotherapies. Asia Pacific is going to be the fastest growing market in the forecasted period, Japan in Asia Pacific has approved the expensive therapeutics such as KYMRIAH which holds strong population base and well contribute in the Asia Pacific market growth.

Major market players included in this report are:

  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Bayer AG
  • Novartis AG
  • Kyowa Kirin Co. Ltd.
  • Bristol Myers Squibb Company
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Sanofi India
  • AbbVie Inc.

Recent Developments in the Market:

  • April 2021 - Kyowa Kirin Co., Ltd. and MEI Pharma Inc. announced the completion of patient enrollment in the global Phase 2 TIDAL study in the primary efficacy follicular lymphoma population.
  • April 2021 - Kyowa Kirin Co., Ltd. and MEI Pharma Inc. announced the completion of patient enrollment in the gl primary efficacy population for follicular lymphoma. * February 2021 - Bristol-Myers Squibb Company Receives FDA Approval of CAR T-Cell Therapy Breyanzi for the Treatment of Large B-Cell Lymphoma in Patients Who Relapsed After Two Other Systematic Treatments or Responded to Previous Therapy announced that it had received Treatment has not been addressed.
  • December 2020 - AstraZeneca announced that Calquence, an anti-cancer drug used to treat patients with mantle cell lymphoma, has shown positive responses in a Phase 2 clinical trial.

Global Non - Hodgkin Lymphoma Therapeutics Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered By Therapy, Disease Type, Distribution channel, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others

By Disease Type:

  • B-cell Lymphoma
  • T-cell Lymphoma

By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Non-Hodgkin lymphoma treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Non-Hodgkin lymphoma treatment Market, by Therapy, 2019-2029 (USD Billion)
    • 1.2.3. Non-Hodgkin lymphoma treatment Market, by Disease, 2019-2029 (USD Billion)
    • 1.2.4. Non-Hodgkin lymphoma treatment Market, by Distribution, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Non-Hodgkin lymphoma treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Non-Hodgkin lymphoma treatment Market Dynamics

  • 3.1. Non-Hodgkin lymphoma treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing investments by Market players
      • 3.1.1.2. Rising Demand for oral drugs
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Non-Hodgkin lymphoma treatment
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in Non-Hodgkin Lymphoma
      • 3.1.3.2. Rising Healthcare Awareness

Chapter 4. Global Non-Hodgkin lymphoma treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Non-Hodgkin lymphoma treatment Market, by Therapy

  • 6.1. Market Snapshot
  • 6.2. Global Non-Hodgkin lymphoma treatment Market by Therapy, Performance - Potential Analysis
  • 6.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Therapy 2019-2029 (USD Billion)
  • 6.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy
    • 6.4.3. Immunotherapy
    • 6.4.4. Others

Chapter 7. Global Non-Hodgkin lymphoma treatment Market, by Disease type

  • 7.1. Market Snapshot
  • 7.2. Global Non-Hodgkin lymphoma treatment Market by Disease type, Performance - Potential Analysis
  • 7.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Disease type 2019-2029 (USD Billion)
  • 7.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 7.4.1. B-Cell Lymphoma
    • 7.4.2. T-cell Lymphoma

Chapter 8. Global Non-Hodgkin lymphoma treatment Market, by Distribution channel

  • 8.1. Market Snapshot
  • 8.2. Global Non-Hodgkin lymphoma treatment Market by Distribution channel, Performance - Potential Analysis
  • 8.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Distribution channel 2019-2029 (USD Billion)
  • 8.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail pharmacies
    • 8.4.3. Others

Chapter 9. Global Non-Hodgkin lymphoma treatment Market, Regional Analysis

  • 9.1. Non-Hodgkin lymphoma treatment Market, Regional Market Snapshot
  • 9.2. North America Non-Hodgkin lymphoma treatment Market
    • 9.2.1. U.S. Non-Hodgkin lymphoma treatment Market
      • 9.2.1.1. Therapy breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Disease type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Non-Hodgkin lymphoma treatment Market
  • 9.3. Europe Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.3.1. U.K. Non-Hodgkin lymphoma treatment Market
    • 9.3.2. Germany Non-Hodgkin lymphoma treatment Market
    • 9.3.3. France Non-Hodgkin lymphoma treatment Market
    • 9.3.4. Spain Non-Hodgkin lymphoma treatment Market
    • 9.3.5. Italy Non-Hodgkin lymphoma treatment Market
    • 9.3.6. Rest of Europe Non-Hodgkin lymphoma treatment Market
  • 9.4. Asia-Pacific Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.4.1. China Non-Hodgkin lymphoma treatment Market
    • 9.4.2. India Non-Hodgkin lymphoma treatment Market
    • 9.4.3. Japan Non-Hodgkin lymphoma treatment Market
    • 9.4.4. Australia Non-Hodgkin lymphoma treatment Market
    • 9.4.5. South Korea Non-Hodgkin lymphoma treatment Market
    • 9.4.6. Rest of Asia Pacific Non-Hodgkin lymphoma treatment Market
  • 9.5. Latin America Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.5.1. Brazil Non-Hodgkin lymphoma treatment Market
    • 9.5.2. Mexico Non-Hodgkin lymphoma treatment Market
  • 9.6. Rest of The World Non-Hodgkin lymphoma treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Takeda Pharmaceutical Company Limited
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. AstraZeneca plc
    • 10.2.3. Bayer AG
    • 10.2.4. Novartis AG
    • 10.2.5. Kyowa Kirin Co. Ltd.
    • 10.2.6. Bristol Myers Squibb Company
    • 10.2.7. Janssen Pharmaceuticals Inc.
    • 10.2.8. Merck & Co. Inc.
    • 10.2.9. Sanofi India
    • 10.2.10. AbbVie. Inc

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Non-Hodgkin lymphoma treatment Market, report scope
  • TABLE 2. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Therapy 2019-2029 (USD Billion)
  • TABLE 4. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Disease type 2019-2029 (USD Billion)
  • TABLE 5. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Distribution channel 2019-2029 (USD Billion)
  • TABLE 6. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Non-Hodgkin lymphoma treatment Market
  • TABLE 71. List of primary sources, used in the study of global Non-Hodgkin lymphoma treatment Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Non-Hodgkin lymphoma treatment Market, research methodology
  • FIG 2. Global Non-Hodgkin lymphoma treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Non-Hodgkin lymphoma treatment Market, key trends 2021
  • FIG 5. Global Non-Hodgkin lymphoma treatment Market, growth prospects 2022-2029
  • FIG 6. Global Non-Hodgkin lymphoma treatment Market, porters 5 force model
  • FIG 7. Global Non-Hodgkin lymphoma treatment Market, pest analysis
  • FIG 8. Global Non-Hodgkin lymphoma treatment Market, value chain analysis
  • FIG 9. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Non-Hodgkin lymphoma treatment Market, Regional snapshot 2019 & 2029
  • FIG 15. North America Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Non-Hodgkin lymphoma treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable